Bachem

Bubendorf, CH
Find alternatives to Bachem for Oligonucleotide →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
79.5
Signal Score
✓ FDA Inspections (5) ○ Clinical Trials ○ SEC Filings ✓ Press (20) ○ EMA GMP ○ MHRA GMP ✓ HC GMP (19)

Quick Facts: Bachem

Signal Score
79.5/100 (as of 2026-10-29)
Quality Compliance
94.4/100
Headquarters
Bubendorf, CH
Modalities
Oligonucleotide
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Bachem

Global leader in peptide and oligonucleotide manufacturing.

Signal Score & Pillar Breakdown

Quality Compliance 94.4
FDA Inspections5 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-05-20)
Most Recent HC OutcomeCompliant · 2025-03-20
HC Attribution19 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesOligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 75.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity 58.0
3 manufacturing sites
Sites: Bubendorf, Switzerland, Torrance, CA, Vista, CA
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
Press Signals20 articles (not scored)
3 manufacturing sites

Bachem FDA Inspection History

2026-05
2026-05
2024-08
2024-06
2023-03
NAI VAI OAI
Date Site Type 483 citations posted Classification
2026-05-20
Bachem Americas, Inc.
Vista, California Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2026-05-04
Bachem Americas, Inc.
Torrance, California Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-08-16
Bachem AG
Bubendorf Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-06-28
Bachem Americas, Inc.
Torrance, California Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-03-27
Bachem Americas, Inc.
Vista, California Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

general (non-sterile) · 2 sites

  • Bubendorf, Switzerland · Bachem AG — general (non-sterile) · valid to Dec 2, 2027
  • Torrance, United States · Bachem Americas, Inc. — general (non-sterile) · valid to Jun 18, 2027

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity 34 open roles Beta

From public job postings on Bachem's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
34
open roles
20
in manufacturing, quality, PD/MSAT, engineering or regulatory (59%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 18, 2026: 0 new postings, 52 taken down.
What this may mean
  • 2 postings use start-up or expansion wording in the title. Read the posting before assuming a new facility; the wording is sometimes routine.
By function
Manufacturing & operations 2
Quality (QA / QC) 6
Engineering & facilities 12
Commercial, BD & client projects 1
Other (finance, HR, IT, other) 13
By site
Bubendorf profile site
2 mfg/ops · 6 QA/QC · 3 eng. · 11 other
22
Stein
· 5 eng. · 2 other
7
Vista profile site
· 3 eng. · 1 other
4
Torrance profile site
· 1 eng.
1
Modality words in job titles
Oligonucleotide2
Notable roles
Senior Commissioning & Qualification (C&Q) Lead Start-up / expansion wording · Bubendorf
Latest postings
Lead of CoE Process Safety Other (finance, HR, IT, other) · Bubendorf
Lead of CoE Industrial Hygiene & Occupational Health Other (finance, HR, IT, other) · Bubendorf
Lead of CoE HSE Digital Systems Other (finance, HR, IT, other) · Bubendorf
Senior Manager Global QMS Transformation Other (finance, HR, IT, other) · Bubendorf
Sr. Manager, Automation Engineering Engineering & facilities · Vista
Sr. Engineering Project Manager Commercial, BD & client projects · Vista
Sr. Automation Engineer Engineering & facilities · Vista
Specialist Cleaning Validation Quality (QA / QC) · Bubendorf
Senior Commissioning & Qualification (C&Q) Lead Engineering & facilities · Bubendorf
Schnuppertag Laborantin Fachrichtung Chemie Quality (QA / QC) · Bubendorf
Schnuppertag Chemie und Pharmatechnologe login Other (finance, HR, IT, other) · Bubendorf
Coverage: counted from Bachem's own careers board. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: careers.bachem.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-04-28
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside?  AD HOC NEWS
general 2026-04-28
Bachem (BANB) CMD 2024 Summary - Quartr
Bachem (BANB) CMD 2024 Summary  Quartr
general 2026-04-18
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to drive sustained growth fo - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to drive sustained growth fo  AD HOC NEWS
general 2026-04-18
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to drive sustained growth fo - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to drive sustained growth fo  AD HOC NEWS
general 2026-04-14
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside?  AD HOC NEWS
general 2026-04-14
BANB.SW Stock Surges 12% on April 14 as Bachem Leads Gainers - Meyka
BANB.SW Stock Surges 12% on April 14 as Bachem Leads Gainers  Meyka
general 2026-04-10
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside? - AD HOC NEWS
Bachem Holding AG stock (CH0012530207): Is peptide demand strong enough to unlock new upside?  AD HOC NEWS
general 2026-04-07
Bachem Holding AG stock: What investors need to know right now - AD HOC NEWS
Bachem Holding AG stock: What investors need to know right now  AD HOC NEWS
general 2026-04-07
Bachem Holding AG stock: What investors need to know right now - AD HOC NEWS
Bachem Holding AG stock: What investors need to know right now  AD HOC NEWS
facility_expansion 2026-03-24
Bachem Holding AG stock faces operational push amid peptide market expansion and biotech demand surg - AD HOC NEWS
Bachem Holding AG stock faces operational push amid peptide market expansion and biotech demand surg  AD HOC NEWS
regulatory 2026-03-24
Bachem Holding AG stock faces biotech sector headwinds amid peptide market slowdown in 2026 - AD HOC NEWS
Bachem Holding AG stock faces biotech sector headwinds amid peptide market slowdown in 2026  AD HOC NEWS
general 2026-03-24
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge - AD HOC NEWS
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge  AD HOC NEWS
general 2026-03-24
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge - AD HOC NEWS
Bachem Holding AG Stock Gains Traction on SIX Swiss Exchange Amid Peptide Demand Surge  AD HOC NEWS
general 2026-03-18
Berenberg Sticks With Bachem After A Strong 2025 - Finimize
Berenberg Sticks With Bachem After A Strong 2025  Finimize
general 2026-03-16
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience - AD HOC NEWS
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience  AD HOC NEWS
general 2026-03-16
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience - AD HOC NEWS
Bachem Holding AG stock under scrutiny as peptide cycle and order trends test patience  AD HOC NEWS
regulatory 2026-03-14
Bachem posts surging sales and profit in 2025 - Indian Chemical News
Bachem posts surging sales and profit in 2025  Indian Chemical News
general 2026-03-12
Bachem Reports Strong Sales Growth and Sustained High Profitability - Barchart
Bachem Reports Strong Sales Growth and Sustained High Profitability  Barchart
general 2026-03-12
Bachem Reports Strong Sales Growth and Sustained High Profitability - BioSpace
Bachem Reports Strong Sales Growth and Sustained High Profitability  BioSpace
general 2026-03-06
Bachem Holding AG (CH0012530207): What Peptide Specialist Investors Need to Know in 2026 - AD HOC NEWS
Bachem Holding AG (CH0012530207): What Peptide Specialist Investors Need to Know in 2026  AD HOC NEWS

Frequently Asked Questions About Bachem

How many FDA inspections does Bachem have on record?
CDMO Signal tracks 5 FDA inspections for Bachem, sourced from the FDA inspection database. See the full inspection history above.
Has Bachem received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Bachem.
What is Bachem's CDMO Signal Score?
Bachem has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating Bachem for a manufacturing program?
Use the free AI matchmaker to compare Bachem against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Oligonucleotide CDMOs →

Similar CDMOs

Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Kaneka Eurogentec
Seraing, BE
Signal Score: 81.6
mRNA, Plasmid, Oligonucleotide
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.5
mRNA, Oligonucleotide, Biologics

Compare Bachem with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Bachem
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.